Olaparib Maintenance Fails in Platinum Sensitive Advanced Non-Small Cell Lung Cancer
Results from early halted PIPSeN study in chemonaïve patients with non-small cell lung cancer without EGFR or ALK/ROS alterations
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1586 results
Data Collection Analysis Demonstrates Changes in Lung Cancer Management Throughout the UK During the First Wave of the COVID-19 Pandemic
Changes were made in the delivery of radical radiotherapy across the UK in response to COVID-19 adapted guidelines
Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer
Data with approximately 3 years of follow-up from the KEYNOTE-407 study show improved survival with pembrolizumab added to chemotherapy
Many Patients with NSCLC Show Targetable Alterations in the PI3K Pathway
Molecular characterisation of tumours with alterations in the PIK3 pathway
Rise in Brain Metastases Detected in Patients with Stage IV NSCLC During COVID-19 Pandemic
More patients diagnosed with stage IV non-small cell lung cancer presented with brain metastases compared to historic rates
Prevalence of ALK Alterations in Non-Small Cell Lung Cancer Determined
Findings from a large analysis of the GENIE Cohort v8.1
Determination of the Incidence of Driver Mutations in Patients with NSCLC and Brain Metastases
Agents with CNS activity may have improved outcomes for patients with non-small cell lung cancer and brain metastases at diagnosis
Artificial Intelligence May Aid in the Discrimination of Radiation Pneumonitis from COVID-19-Associated Interstitial Pneumonia
A deep-learning algorithm can help to discriminate radiation pneumonitis from COVID-19 pneumonia
Socioeconomic Deprivation Associated with Worse Survival in Patients with Cancer Included in Clinical Trials
It is needed to understand if the cause of disparity is related to reduced access to supportive care or post-protocol therapy
Factors Associated with COVID-19 Severity Among Patients with Cancer
Findings from the COVID-19 and Cancer Consortium
FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma
Evidence for efficacy is based on the results from the ZUMA-5 study
High Tumour Mutation Burden Fails to Predict Response to Immune Checkpoint Inhibitors Across All Cancer Types
Cancer types where TMB-H does not predict response generally show no relationship between tumour neoantigen load and CD8 T-cell infiltration